RESULTS	O
:	O
Prenatal	O
screening	O
rates	O
for	O
hepatitis	B-Disease
B	I-Disease
(	O
98	O
.	O
8	O
%	O
)	O
and	O
rubella	B-Disease
(	O
99	O
.	O
4	O
%	O
)	O
were	O
high	O
.	O

Pregnenolone	B-Chemical
sulphate	I-Chemical
(	O
PREGS	B-Chemical
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

PATIENTS	O
:	O
Sixty	O
patients	O
were	O
pretreated	O
in	O
a	O
randomized	O
double	O
-	O
blinded	O
fashion	O
with	O
remifentanil	B-Chemical
1	O
microg	O
/	O
kg	O
or	O
placebo	O
.	O

AZT	B-Chemical
has	O
induced	O
a	O
macrocytic	B-Disease
anemia	I-Disease
in	O
AIDS	B-Disease
patients	O
on	O
long	O
term	O
AZT	B-Chemical
therapy	O
.	O

METHODS	O
:	O
Rats	O
were	O
treated	O
with	O
intravenous	O
doxorubicin	B-Chemical
(	O
1	O
mg	O
kg	O
(	O
-	O
1	O
)	O
week	O
(	O
-	O
1	O
)	O
)	O
for	O
7	O
weeks	O
and	O
were	O
sacrificed	O
either	O
1	O
week	O
(	O
'	O
short	O
-	O
term	O
'	O
)	O
or	O
30	O
weeks	O
(	O
'	O
long	O
-	O
term	O
'	O
)	O
following	O
the	O
last	O
dose	O
.	O

It	O
was	O
concluded	O
that	O
morphine	B-Chemical
catalepsy	B-Disease
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	B-Chemical
induced	O
by	O
nicotine	B-Chemical
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O

In	O
contrast	O
,	O
the	O
conduction	O
velocity	O
,	O
the	O
number	O
and	O
size	O
of	O
axons	O
in	O
the	O
optic	O
nerve	O
,	O
and	O
the	O
specific	O
localization	O
of	O
Na	B-Chemical
(	O
v	O
)	O
1	O
.	O
6	O
channels	O
in	O
the	O
nodes	O
of	O
Ranvier	O
were	O
unchanged	O
.	O

Maximal	O
CS	B-Chemical
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

Sixty	O
-	O
five	O
patients	O
,	O
34	O
women	O
and	O
31	O
men	O
,	O
ages	O
36	O
to	O
80	O
years	O
,	O
received	O
either	O
normal	O
saline	O
before	O
and	O
after	O
TDI	O
(	O
group	O
1	O
)	O
,	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-Chemical
before	O
and	O
saline	O
after	O
TDI	O
(	O
group	O
2	O
)	O
,	O
or	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-Chemical
before	O
and	O
after	O
TDI	O
(	O
group	O
3	O
)	O
.	O

One	O
had	O
baseline	O
bicuspid	B-Disease
aortic	I-Disease
valve	I-Disease
and	O
mild	O
aortic	B-Disease
regurgitation	I-Disease
that	O
progressed	O
to	O
moderate	O
regurgitation	O
.	O

Nineteen	O
patients	O
had	O
Zollinger	B-Disease
-	I-Disease
Ellison	I-Disease
syndrome	I-Disease
,	O
one	O
patient	O
had	O
systemic	B-Disease
mastocytosis	I-Disease
,	O
and	O
two	O
patients	O
had	O
idiopathic	O
hypersecretion	O
.	O

The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	B-Chemical
,	O
a	O
polyphenol	B-Chemical
from	O
Mangifera	O
indica	O
Linn	O
.	O

Although	O
most	O
patients	O
were	O
receiving	O
several	O
drugs	O
,	O
Mellaril	B-Chemical
(	O
thioridazine	B-Chemical
)	O
appeared	O
to	O
be	O
responsible	O
for	O
five	O
cases	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
,	O
one	O
of	O
which	O
was	O
fatal	O
in	O
a	O
35	O
year	O
old	O
woman	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	B-Disease
(	O
not	O
significant	O
)	O
.	O

Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	B-Disease
abuse	I-Disease
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	B-Chemical
induced	O
platelet	B-Disease
aggregation	I-Disease
who	O
require	O
brief	O
reexposure	O
to	O
heparin	B-Chemical
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	B-Disease
syndrome	O
is	O
not	O
well	O
defined	O
.	O

Despite	O
the	O
advent	O
of	O
calcium	B-Chemical
channel	O
blockers	O
and	O
beta	O
-	O
adrenergic	O
antagonists	O
,	O
ergot	B-Chemical
preparations	O
continue	O
to	O
play	O
a	O
major	O
role	O
in	O
migraine	B-Disease
therapy	O
,	O
so	O
that	O
the	O
danger	O
of	O
St	B-Disease
.	I-Disease

Pretreatment	O
with	O
dexamethasone	B-Chemical
is	O
not	O
justified	O
to	O
prevent	O
postoperative	B-Disease
myalgia	I-Disease
after	O
succinylcholine	B-Chemical
.	O

Ketamine	B-Chemical
led	O
to	O
enhanced	O
cortical	O
activations	O
in	O
supramarginal	O
and	O
frontal	O
brain	O
regions	O
for	O
phonological	O
and	O
lexical	O
verbal	O
fluency	O
,	O
but	O
not	O
for	O
semantic	O
verbal	O
fluency	O
.	O

Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	B-Chemical
receptors	O
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O

Does	O
hormone	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B-Disease
cancer	I-Disease
have	O
a	O
detrimental	B-Disease
effect	I-Disease
on	I-Disease
memory	I-Disease
and	I-Disease
cognition	I-Disease
?	O

In	O
contrast	O
,	O
the	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
treatment	O
increased	O
the	O
incidence	O
of	O
lidocaine	B-Chemical
(	O
80	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
-	O
induced	O
convulsions	B-Disease
significantly	O
.	O

The	O
Flumazenil	B-Chemical
in	O
Intravenous	O
Conscious	O
Sedation	O
with	O
Diazepam	B-Chemical
Multicenter	O
Study	O
Group	O
II	O
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
spinal	O
anaesthesia	O
with	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
:	O
a	O
review	O
of	O
six	O
cases	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
1993	O
-	O
1997	O
.	O

Serum	O
alpha	O
-	O
GST	O
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	B-Disease
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	B-Disease
of	O
the	O
liver	O
capsule	O
,	O
necrosis	B-Disease
,	O
and	O
steatosis	B-Disease
throughout	O
the	O
study	O
.	O

Scopolamine	B-Chemical
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age	O
-	O
dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	O
of	O
aniracetam	B-Chemical
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	B-Chemical
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	B-Disease
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Discontinuance	O
of	O
quinidine	B-Chemical
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

All	O
24	O
patients	O
with	O
seizures	B-Disease
received	O
high	O
doses	O
of	O
TXA	B-Chemical
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69	O
.	O
9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

In	O
the	O
ischemic	B-Disease
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

All	O
4	O
patients	O
presented	O
with	O
skin	B-Disease
eruptions	I-Disease
that	O
developed	O
after	O
receiving	O
warfarin	B-Chemical
for	O
several	O
years	O
.	O

Two	O
of	O
the	O
64	O
patients	O
in	O
the	O
iodixanol	B-Chemical
group	O
(	O
3	O
percent	O
)	O
had	O
an	O
increase	O
in	O
the	O
creatinine	B-Chemical
concentration	O
of	O
0	O
.	O
5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
as	O
compared	O
with	O
17	O
of	O
the	O
65	O
patients	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
26	O
percent	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
;	O
odds	O
ratio	O
for	O
such	O
an	O
increase	O
in	O
the	O
iodixanol	B-Chemical
group	O
,	O
0	O
.	O
09	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
02	O
to	O
0	O
.	O
41	O
]	O
)	O
.	O

A	O
case	O
of	O
thoraco	O
-	O
abdominal	O
rigidity	B-Disease
leading	O
to	O
respiratory	B-Disease
failure	I-Disease
is	O
described	O
in	O
the	O
post	O
-	O
operative	O
period	O
in	O
an	O
elderly	O
patient	O
who	O
received	O
a	O
moderate	O
dose	O
of	O
fentanyl	B-Chemical
.	O

CONCLUSION	O
:	O
This	O
study	O
documents	O
good	O
compliance	O
in	O
New	O
Hampshire	O
'	O
s	O
birthing	O
hospitals	O
with	O
national	O
guidelines	O
for	O
perinatal	O
hepatitis	B-Disease
B	I-Disease
and	O
rubella	B-Disease
prevention	O
and	O
highlights	O
potential	O
areas	O
for	O
improvement	O
.	O

Remifentanil	B-Chemical
-	O
related	O
complications	O
were	O
assessed	O
during	O
the	O
remifentanil	B-Chemical
infusion	O
,	O
and	O
pain	B-Disease
caused	O
by	O
propofol	B-Chemical
was	O
evaluated	O
using	O
a	O
four	O
-	O
point	O
scale	O
during	O
the	O
propofol	B-Chemical
infusion	O
.	O

In	O
female	O
rats	O
,	O
CP	B-Chemical
200	O
mg	O
.	O
/	O
kg	O
.	O

Cystitis	B-Disease
was	O
evaluated	O
24	O
h	O
after	O
its	O
induction	O
by	O
the	O
changes	O
in	O
bladder	O
wet	O
weight	O
and	O
by	O
macroscopic	O
and	O
microscopic	O
analysis	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
levofloxacin	B-Chemical
500	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
acute	O
bacterial	O
sinusitis	B-Disease
.	O

The	O
reaction	O
was	O
specific	O
to	O
trihexyphenidyl	B-Chemical
and	O
not	O
to	O
other	O
anticholinergic	O
drugs	O
.	O

The	O
most	O
common	O
side	O
effect	O
was	O
dry	B-Disease
month	I-Disease
in	O
5	O
cases	O
(	O
16	O
.	O
7	O
%	O
)	O
with	O
2	O
cases	O
reporting	O
a	O
moderate	O
degree	O
and	O
1	O
case	O
with	O
severe	O
degree	O
.	O

Patients	O
with	O
CHF	B-Disease
on	O
amiodarone	B-Chemical
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	B-Disease
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

Symptoms	O
relief	O
in	O
the	O
group	O
receiving	O
the	O
highest	O
concentration	O
of	O
azelastine	B-Chemical
(	O
2	O
.	O
0	O
mg	O
twice	O
daily	O
)	O
was	O
statistically	O
greater	O
than	O
in	O
the	O
placebo	O
group	O
during	O
all	O
weeks	O
of	O
the	O
study	O
.	O

Although	O
diastolic	O
blood	O
pressure	O
remained	O
unchanged	O
,	O
systolic	O
blood	O
pressure	O
increased	O
from	O
119	O
to	O
135	O
mm	O
Hg	O
(	O
SED	O
+	O
/	O
-	O
3	O
.	O
4	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
associated	O
with	O
an	O
increased	B-Disease
cardiac	I-Disease
output	I-Disease
(	O
5	O
.	O
85	O
-	O
7	O
.	O
73	O
l	O
/	O
min	O
,	O
SED	O
+	O
/	O
-	O
0	O
.	O
46	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	B-Chemical
,	O
hexamethonium	B-Chemical
,	O
and	O
naloxone	B-Chemical
also	O
decreased	O
catalepsy	B-Disease
induced	O
by	O
morphine	B-Chemical
plus	O
nicotine	B-Chemical
.	O

Maximal	O
twitches	O
of	O
the	O
diaphragm	O
were	O
lower	O
in	O
the	O
C	O
group	O
(	O
653	O
+	O
/	O
-	O
174	O
g	O
/	O
cm	O
(	O
2	O
)	O
)	O
than	O
in	O
the	O
M	B-Chemical
group	O
(	O
837	O
+	O
/	O
-	O
171	O
g	O
/	O
cm	O
(	O
2	O
)	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
T	B-Chemical
group	O
(	O
765	O
+	O
/	O
-	O
145	O
g	O
/	O
cm	O
(	O
2	O
)	O
,	O
NS	O
)	O
.	O

Protection	O
with	O
oral	O
MESNA	B-Chemical
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N	B-Chemical
-	I-Chemical
butyl	I-Chemical
-	I-Chemical
deoxynojirimycin	I-Chemical
(	O
SC	B-Chemical
-	I-Chemical
48334	I-Chemical
)	O
and	O
zidovudine	B-Chemical
in	O
patients	O
with	O
HIV	B-Disease
-	I-Disease
1	I-Disease
infection	I-Disease
and	O
200	O
-	O
500	O
CD4	O
cells	O
/	O
mm3	O
.	O

It	O
seems	O
that	O
combined	O
treatment	O
of	O
fluvoxamine	B-Chemical
with	O
phenothiazines	B-Chemical
may	O
possess	O
proconvulsive	O
activity	O
.	O

METHODS	O
:	O
From	O
the	O
Danish	O
National	O
Register	O
of	O
Patients	O
(	O
NRP	O
)	O
,	O
1996	O
to	O
1998	O
,	O
the	O
records	O
of	O
1	O
.	O
1	O
million	O
Danish	O
women	O
,	O
ages	O
15	O
to	O
44	O
years	O
,	O
were	O
searched	O
for	O
evidence	O
of	O
VTE	B-Disease
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	B-Disease
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	B-Chemical
-	I-Chemical
HT6	I-Chemical
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B-Disease
disorders	I-Disease
.	O

The	O
antidiabetic	O
drug	O
metformin	B-Chemical
can	O
diminish	O
apoptosis	O
induced	O
by	O
oxidative	O
stress	O
in	O
endothelial	O
cells	O
and	O
prevent	O
vascular	B-Disease
dysfunction	I-Disease
even	O
in	O
nondiabetic	O
patients	O
.	O

The	O
arrhythmia	B-Disease
resolved	O
after	O
therapy	O
with	O
atenolol	B-Chemical
,	O
but	O
recurred	O
a	O
year	O
later	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	B-Chemical
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
,	O
leading	O
to	O
TDP	B-Disease
.	O

Midazolam	B-Chemical
compared	O
with	O
thiopentone	B-Chemical
as	O
an	O
induction	O
agent	O
.	O

Sixty	O
-	O
nine	O
percent	O
of	O
patients	O
continued	O
treatment	O
with	O
amiodarone	B-Chemical
and	O
had	O
no	O
recurrence	O
of	O
symptomatic	O
VT	B-Disease
or	O
ventricular	B-Disease
fibrillation	I-Disease
(	O
VF	B-Disease
)	O
over	O
a	O
follow	O
-	O
up	O
of	O
6	O
to	O
52	O
months	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
14	O
.	O
2	O
+	O
/	O
-	O
8	O
.	O
2	O
)	O
.	O

Compared	O
with	O
controls	O
,	O
EDDs	B-Disease
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

Streptomycin	B-Chemical
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	B-Chemical
(	O
n	O
=	O
8	O
)	O
or	O
saline	O
(	O
n	O
=	O
6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

Antithrombin	O
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
was	O
administered	O
to	O
rats	O
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
.	O

Tetany	B-Disease
and	O
rhabdomyolysis	B-Disease
due	O
to	O
surreptitious	O
furosemide	B-Chemical
-	O
-	O
importance	O
of	O
magnesium	B-Chemical
supplementation	O
.	O

Behavioral	O
effects	O
of	O
pubertal	O
anabolic	O
androgenic	O
steroid	B-Chemical
exposure	O
in	O
male	O
rats	O
with	O
low	O
serotonin	B-Chemical
.	O

D	O
-	O
1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
or	O
D	O
-	O
2	O
agonist	O
quinpirole	B-Chemical
decreased	O
the	O
catalepsy	B-Disease
induced	O
by	O
fluphenazine	B-Chemical
,	O
SCH	B-Chemical
23390	I-Chemical
or	O
sulpiride	B-Chemical
.	O

Metabotropic	O
glutamate	B-Chemical
7	O
receptor	O
subtype	O
modulates	O
motor	O
symptoms	O
in	O
rodent	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

Hallucinations	B-Disease
and	O
ifosfamide	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O

Administered	O
to	O
healthy	O
volunteers	O
,	O
a	O
subanesthetic	O
dose	O
of	O
the	O
non	O
-	O
competitive	O
NMDA	B-Chemical
receptor	O
antagonist	O
ketamine	B-Chemical
leads	O
to	O
psychopathological	O
symptoms	O
similar	O
to	O
those	O
observed	O
in	O
schizophrenia	B-Disease
.	O

"	O
Eyes	O
-	O
closed	O
"	O
hallucinatory	B-Disease
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O

Epileptogenic	O
activity	O
of	O
folic	B-Chemical
acid	I-Chemical
after	O
drug	O
induces	O
SLE	B-Disease
(	O
folic	B-Chemical
acid	I-Chemical
and	O
epilepsy	B-Disease
)	O

A	O
patient	O
with	O
sinus	O
bradycardia	B-Disease
and	O
atrioventricular	B-Disease
block	I-Disease
,	O
induced	O
by	O
carbamazepine	B-Chemical
,	O
prompted	O
an	O
extensive	O
literature	O
review	O
of	O
all	O
previously	O
reported	O
cases	O
.	O

Steroid	B-Chemical
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	B-Disease
glaucoma	I-Disease
and	O
open	B-Disease
angle	I-Disease
glaucoma	I-Disease
.	O

The	O
patient	O
continued	O
treatment	O
for	O
another	O
4	O
days	O
after	O
the	O
appearance	O
of	O
jaundice	B-Disease
until	O
she	O
finished	O
both	O
medications	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Women	O
who	O
were	O
born	O
between	O
1971	O
and	O
1975	O
had	O
the	O
highest	O
rate	O
of	O
rubella	B-Disease
nonimmunity	O
(	O
9	O
.	O
5	O
%	O
)	O
.	O

Amphotericin	B-Chemical
B	I-Chemical
-	O
induced	O
seizures	B-Disease
in	O
a	O
patient	O
with	O
AIDS	B-Disease
.	O

Ammonia	B-Chemical
coma	B-Disease
was	O
produced	O
in	O
rats	O
within	O
10	O
to	O
15	O
minutes	O
of	O
an	O
intraperitonealinjection	O
of	O
1	O
.	O
7	O
mmol	O
NH4CL	B-Chemical
.	O

We	O
used	O
chloroquine	B-Chemical
or	O
hydroxychloroquine	B-Chemical
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	B-Disease
attributable	O
to	O
these	O
drugs	O
.	O

In	O
Nx	O
dogs	O
,	O
OCT	B-Chemical
reversed	O
abnormal	O
bone	O
formation	O
,	O
such	O
as	O
woven	B-Disease
osteoid	I-Disease
and	O
fibrosis	B-Disease
,	O
but	O
did	O
not	O
significantly	O
alter	O
the	O
level	O
of	O
bone	O
turnover	O
.	O

Topiramate	B-Chemical
is	O
a	O
recently	O
developed	O
antiepileptic	O
medication	O
that	O
is	O
becoming	O
more	O
widely	O
prescribed	O
because	O
of	O
its	O
efficacy	O
in	O
treating	O
refractory	B-Disease
seizures	I-Disease
.	O

This	O
association	O
with	O
uveitis	B-Disease
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

A	O
significant	O
proliferative	O
response	O
to	O
serum	O
collected	O
after	O
dilevalol	B-Chemical
intake	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
patient	O
compared	O
with	O
the	O
proliferative	O
response	O
to	O
the	O
serum	O
collected	O
before	O
the	O
drug	O
intake	O
.	O

The	O
observed	O
effect	O
of	O
NIMO	B-Chemical
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-Chemical
homeostasis	O
during	O
hypotension	B-Disease
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	O
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	B-Chemical
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O

PR3	O
-	O
ANCA	O
titer	O
was	O
250	O
and	O
1	O
,	O
070	O
EU	O
in	O
pleural	B-Disease
effusions	I-Disease
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Recent	O
preclinical	O
studies	O
have	O
focused	O
on	O
the	O
intracellular	O
formation	O
of	O
CB	B-Chemical
3717	I-Chemical
polyglutamates	O
.	O

Potassium	B-Chemical
depletion	O
also	O
potentiates	O
the	O
tubular	O
toxicity	B-Disease
of	O
AmB	B-Chemical
.	O

Relation	O
of	O
perfusion	O
defects	O
observed	O
with	O
myocardial	O
contrast	O
echocardiography	O
to	O
the	O
severity	O
of	O
coronary	B-Disease
stenosis	I-Disease
:	O
correlation	O
with	O
thallium	B-Chemical
-	O
201	O
single	O
-	O
photon	O
emission	O
tomography	O
.	O

Ventricular	O
DNA	O
content	O
was	O
unchanged	O
during	O
the	O
early	O
stage	O
(	O
1	O
-	O
4	O
days	O
)	O
of	O
hypertrophic	B-Disease
growth	O
but	O
increased	O
to	O
a	O
new	O
steady	O
-	O
state	O
level	O
19	O
%	O
above	O
the	O
controls	O
after	O
8	O
days	O
of	O
treatment	O
.	O

We	O
think	O
that	O
even	O
these	O
lower	O
dosages	O
of	O
cyclosporine	B-Chemical
can	O
cause	O
chronic	O
nephrotoxicity	B-Disease
and	O
that	O
further	O
modification	O
of	O
the	O
immunosuppressive	O
regimen	O
is	O
required	O
to	O
completely	O
abolish	O
this	O
toxic	O
side	O
effect	O
.	O

Worsening	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
by	O
motor	O
and	O
mental	O
tasks	O
.	O

To	O
elucidate	O
the	O
possible	O
role	O
of	O
the	O
kinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
during	O
the	O
development	O
of	O
DOX	B-Chemical
cardiomyopathy	B-Disease
,	O
we	O
studied	O
B1R	O
knockout	O
mice	O
(	O
B1R	O
(	O
-	O
/	O
-	O
)	O
)	O
by	O
investigating	O
cardiac	O
inflammation	B-Disease
and	O
apoptosis	O
after	O
induction	O
of	O
DOX	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
.	O

Half	O
-	O
relaxation	O
time	O
was	O
prolonged	O
in	O
both	O
steroid	B-Chemical
groups	O
,	O
and	O
time	O
to	O
peak	O
tension	O
was	O
longer	O
with	O
M	B-Chemical
,	O
whereas	O
tetanic	B-Disease
tensions	O
were	O
similar	O
.	O

BACKGROUND	O
:	O
Dexmedetomidine	B-Chemical
has	O
been	O
used	O
at	O
our	O
institution	O
since	O
2005	O
to	O
provide	O
sedation	O
for	O
pediatric	O
radiological	O
imaging	O
studies	O
.	O

Second	O
-	O
and	O
third	O
-	O
generation	O
cephalosporins	B-Chemical
,	O
especially	O
cefotetan	B-Chemical
,	O
are	O
increasingly	O
associated	O
with	O
severe	O
,	O
sometimes	O
fatal	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Sirolimus	B-Chemical
and	O
mycophenolate	B-Chemical
mofetil	I-Chemical
for	O
calcineurin	O
-	O
free	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

These	O
possibilities	O
stress	O
the	O
importance	O
of	O
developing	O
a	O
safe	O
and	O
effective	O
approach	O
to	O
drug	O
-	O
induced	O
hyperprolactinemia	B-Disease
in	O
youth	O
.	O

This	O
neuropathy	B-Disease
was	O
gradually	O
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	O
received	O
allogeneic	O
bone	O
marrow	O
transplantation	O
,	O
the	O
symptoms	O
worsened	O
,	O
with	O
the	O
development	O
of	O
graft	B-Disease
-	I-Disease
versus	I-Disease
-	I-Disease
host	I-Disease
disease	I-Disease
,	O
and	O
the	O
symptoms	O
subsequently	O
responded	O
to	O
methylprednisolone	B-Chemical
.	O

Hepatotoxicity	B-Disease
and	O
malaise	B-Disease
are	O
again	O
the	O
most	O
frequent	O
side	O
effects	O
.	O

The	O
pattern	O
of	O
the	O
aplastic	B-Disease
anemia	I-Disease
was	O
associated	O
with	O
an	O
idiosyncratic	O
response	O
to	O
chloramphenicol	B-Chemical
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
in	O
humans	O
.	O

Alterations	O
of	O
norepinephrine	B-Chemical
transporter	O
(	O
NET	O
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	O
in	O
relation	O
to	O
sensitization	O
to	O
seizures	B-Disease
induce	O
by	O
cocaine	B-Chemical
and	O
local	O
anesthetics	O
were	O
studied	O
in	O
mice	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	B-Chemical
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)	I-Chemical
-	I-Chemical
IsoP	I-Chemical
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	B-Disease
,	O
steatosis	B-Disease
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	O
-	O
GST	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	B-Disease
of	I-Disease
the	I-Disease
left	I-Disease
internal	I-Disease
carotid	I-Disease
artery	I-Disease
(	O
ICA	O
)	O
.	O

Oxacillin	B-Chemical
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	B-Chemical
.	O

Tacrine	B-Chemical
,	O
administered	O
in	O
LiCl	B-Chemical
pre	O
-	O
treated	O
rats	O
,	O
induces	O
electrocorticographic	O
seizures	B-Disease
and	O
delayed	O
hippocampal	B-Disease
damage	I-Disease
.	O

CONCLUSIONS	O
:	O
In	O
our	O
series	O
,	O
the	O
occurrence	O
of	O
HIT	B-Disease
after	O
liver	O
transplantation	O
was	O
uncommon	O
.	O

In	O
one	O
patient	O
,	O
enflurane	B-Chemical
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	B-Disease
.	O

Nephrotoxicity	B-Disease
associated	O
with	O
ciprofloxacin	B-Chemical
is	O
uncommon	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	B-Chemical
iodide	I-Chemical
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	B-Disease
weakness	I-Disease
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	B-Disease
gravis	I-Disease
.	O

Case	O
report	O
:	O
Dexatrim	B-Chemical
(	O
Phenylpropanolamine	B-Chemical
)	O
as	O
a	O
cause	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Two	O
different	O
schedules	O
of	O
CBDCA	B-Chemical
administration	O
(	O
10	O
mg	O
/	O
kg	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
twice	O
a	O
week	O
for	O
nine	O
times	O
)	O
were	O
evaluated	O
in	O
Wistar	O
rats	O
.	O

The	O
effectiveness	O
of	O
chronic	O
but	O
not	O
repeated	O
,	O
intermittent	O
injections	O
of	O
CBZ	B-Chemical
suggests	O
that	O
different	O
biochemical	O
consequences	O
result	O
from	O
the	O
different	O
treatment	O
regimens	O
.	O

Respiratory	B-Disease
failure	I-Disease
rapidly	O
ensued	O
and	O
both	O
patients	O
expired	O
in	O
spite	O
of	O
efforts	O
at	O
resuscitation	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	B-Disease
should	O
be	O
noted	O
in	O
elderly	O
depressive	B-Disease
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	B-Disease
,	O
agitation	B-Disease
,	O
malnutrition	B-Disease
,	O
and	O
exhaustion	O
.	O

On	O
the	O
whole	O
,	O
the	O
differences	O
between	O
midazolam	B-Chemical
and	O
thiopentone	B-Chemical
had	O
no	O
apparent	O
clinical	O
consequences	O
.	O

Prenatal	O
exposure	O
to	O
fluoxetine	B-Chemical
induces	O
fetal	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
in	O
the	O
rat	O
.	O

Oxytocin	B-Chemical
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	B-Disease
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	B-Disease
intoxication	I-Disease
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	B-Disease
,	O
muscular	O
irritability	B-Disease
,	O
or	O
headaches	B-Disease
.	O

These	O
findings	O
indicate	O
that	O
dobutamine	B-Chemical
can	O
provoke	O
coronary	B-Disease
spasm	I-Disease
in	O
some	O
patients	O
with	O
coronary	B-Disease
spastic	I-Disease
angina	I-Disease
.	O

We	O
measured	O
the	O
degree	O
of	O
morphologic	O
damage	O
by	O
ultrastructural	O
examination	O
of	O
endomyocardial	O
biopsy	O
and	O
the	O
degree	O
of	O
performance	O
abnormally	O
by	O
right	O
heart	O
catheterization	O
in	O
patients	O
receiving	O
DXR	B-Chemical
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	B-Disease
disturbances	I-Disease
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	B-Chemical
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	B-Chemical
-	O
associated	O
myalgia	B-Disease
.	O

We	O
suggest	O
that	O
our	O
observations	O
are	O
additional	O
proof	O
of	O
the	O
functional	O
somatotopy	O
of	O
the	O
systems	O
within	O
the	O
GPi	O
that	O
mediate	O
parkinsonism	B-Disease
and	O
dyskinesias	B-Disease
,	O
especially	O
along	O
the	O
dorsoventral	O
trajectory	O
used	O
in	O
pallidotomy	O
.	O

Cerebral	B-Disease
sinus	I-Disease
thrombosis	I-Disease
as	O
a	O
potential	O
hazard	O
of	O
antifibrinolytic	O
treatment	O
in	O
menorrhagia	B-Disease
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
including	O
akathisia	B-Disease
,	O
with	O
quetiapine	B-Chemical
in	O
patients	O
with	O
bipolar	B-Disease
mania	I-Disease
.	O

Pre	O
-	O
treatment	O
with	O
ketamine	B-Chemical
produced	O
cross	O
-	O
tolerance	O
to	O
morphine	B-Chemical
,	O
whereas	O
pretreatment	O
with	O
morphine	B-Chemical
did	O
not	O
induce	O
cross	O
-	O
tolerance	O
to	O
ketamine	B-Chemical
but	O
rather	O
augmented	O
the	O
cataleptic	B-Disease
response	O
;	O
this	O
augmentation	O
was	O
attributed	O
to	O
residual	O
morphine	B-Chemical
in	O
the	O
brain	O
.	O

In	O
a	O
separate	O
group	O
of	O
mice	O
not	O
subjected	O
to	O
behavioral	O
studies	O
,	O
the	O
same	O
dose	O
of	O
NTG	B-Chemical
(	O
n	O
=	O
3	O
)	O
and	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
sem	O
to	O
31	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
8	O
mm	O
Hg	O
sem	O
and	O
from	O
86	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
7	O
mm	O
Hg	O
sem	O
to	O
32	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
mm	O
Hg	O
sem	O
,	O
respectively	O
.	O

In	O
our	O
patient	O
,	O
both	O
supraphysiologic	O
levels	O
of	O
plasma	O
catecholamines	B-Chemical
and	O
stress	O
related	O
neuropeptides	O
caused	O
by	O
cancer	B-Disease
diagnosis	O
as	O
well	O
as	O
chemotherapy	O
may	O
have	O
contributed	O
the	O
development	O
of	O
ABS	B-Disease
.	O

To	O
examine	O
the	O
relationship	O
between	O
quantitative	O
stimulant	O
drug	O
levels	O
,	O
catecholamines	B-Chemical
,	O
and	O
psychotic	B-Disease
symptoms	I-Disease
,	O
nineteen	O
patients	O
in	O
a	O
psychiatric	B-Disease
emergency	O
service	O
with	O
a	O
diagnosis	O
of	O
amphetamine	B-Chemical
-	O
or	O
cocaine	B-Chemical
-	O
induced	O
psychosis	B-Disease
were	O
interviewed	O
,	O
and	O
plasma	O
and	O
urine	O
were	O
collected	O
for	O
quantitative	O
assays	O
of	O
stimulant	O
drug	O
and	O
catecholamine	B-Chemical
metabolite	O
levels	O
.	O

The	O
etiology	O
of	O
pyeloureteritis	B-Disease
cystica	I-Disease
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	B-Disease
and	O
inflammation	B-Disease
.	O

RESULTS	O
:	O
Both	O
valsartan	B-Chemical
and	O
amlodipine	B-Chemical
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

As	O
inhibitors	O
of	O
isolated	O
L1210	O
TS	O
,	O
CB	O
3717	O
di	O
-	O
,	O
tri	O
-	O
,	O
tetra	O
-	O
and	O
pentaglutamate	O
are	O
26	O
-	O
,	O
87	O
-	O
,	O
119	O
-	O
and	O
114	O
-	O
fold	O
more	O
potent	O
than	O
CB	B-Chemical
3717	I-Chemical
,	O
respectively	O
,	O
and	O
their	O
formation	O
may	O
,	O
therefore	O
,	O
be	O
an	O
important	O
determinant	O
of	O
CB	B-Chemical
3717	I-Chemical
cytotoxicity	B-Disease
.	O

Tic	B-Disease
disorders	I-Disease
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	B-Chemical
,	O
olanzapine	B-Chemical
and	O
ziprasidone	B-Chemical
.	O

In	O
contrast	O
,	O
2R	B-Chemical
,	I-Chemical
4R	I-Chemical
-	I-Chemical
APDC	I-Chemical
injections	O
were	O
ineffective	O
.	O

After	O
the	O
end	O
of	O
the	O
treatment	O
,	O
the	O
number	O
and	O
the	O
size	O
of	O
induced	O
PAS	O
positive	O
preneoplastic	B-Disease
foci	I-Disease
was	O
significantly	O
reduced	O
when	O
PB	B-Chemical
was	O
given	O
simultaneously	O
with	O
DEN	B-Chemical
for	O
4	O
and	O
6	O
weeks	O
.	O

The	O
incidence	O
rate	O
of	O
thromboembolism	B-Disease
was	O
0	O
.	O
9	O
%	O
for	O
all	O
the	O
studies	O
and	O
0	O
.	O
5	O
,	O
0	O
,	O
20	O
,	O
and	O
0	O
%	O
in	O
groups	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
;	O
for	O
hemorrhage	B-Disease
,	O
the	O
overall	O
rate	O
was	O
3	O
.	O
4	O
%	O
(	O
3	O
.	O
8	O
,	O
2	O
.	O
6	O
,	O
10	O
,	O
and	O
0	O
%	O
for	O
the	O
respective	O
groups	O
)	O
.	O

Is	O
phenytoin	B-Chemical
administration	O
safe	O
in	O
a	O
hypothermic	B-Disease
child	O
?	O

BACKGROUND	O
:	O
Calcitriol	B-Chemical
therapy	O
suppresses	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
patients	O
with	O
renal	B-Disease
failure	I-Disease
but	O
has	O
several	O
drawbacks	O
,	O
including	O
hypercalcemia	B-Disease
and	O
/	O
or	O
marked	O
suppression	B-Disease
of	I-Disease
bone	I-Disease
turnover	I-Disease
,	O
which	O
may	O
lead	O
to	O
adynamic	B-Disease
bone	I-Disease
disease	I-Disease
.	O

In	O
groups	O
given	O
2	O
%	O
BHA	B-Chemical
,	O
although	O
marked	O
hyperplastic	O
changes	O
of	O
the	O
forestomach	O
epithelium	O
were	O
observed	O
in	O
all	O
animals	O
,	O
co	O
-	O
administration	O
of	O
0	O
.	O
25	O
%	O
RA	B-Chemical
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
the	O
incidence	O
of	O
forestomach	B-Disease
tumors	I-Disease
(	O
squamous	B-Disease
cell	I-Disease
papilloma	I-Disease
and	O
carcinoma	B-Disease
)	O
to	O
60	O
%	O
(	O
9	O
/	O
15	O
,	O
2	O
rats	O
with	O
carcinoma	B-Disease
)	O
from	O
15	O
%	O
(	O
3	O
/	O
20	O
,	O
one	O
rat	O
with	O
carcinoma	B-Disease
)	O
in	O
the	O
group	O
given	O
RA	B-Chemical
-	O
free	O
water	O
.	O

Diltiazem	B-Chemical
was	O
used	O
as	O
a	O
comparison	O
drug	O
and	O
autonomic	O
blockade	O
with	O
atropine	B-Chemical
and	O
nadolol	B-Chemical
was	O
applied	O
in	O
some	O
experiments	O
.	O

Rats	O
were	O
administered	O
fenoldopam	B-Chemical
for	O
24	O
hours	O
by	O
intravenous	O
infusion	O
with	O
or	O
without	O
following	O
repeated	O
daily	O
oral	O
administrations	O
of	O
theophylline	B-Chemical
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
presented	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
(	O
RPGN	B-Disease
)	O
after	O
5	O
months	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
(	O
250	O
mg	O
/	O
day	O
)	O
treatment	O
.	O

This	O
case	O
report	O
describes	O
a	O
generalized	O
seizure	B-Disease
associated	O
with	O
sustained	O
-	O
release	O
bupropion	B-Chemical
use	O
and	O
sleep	B-Disease
deprivation	I-Disease
.	O

The	O
toxicity	B-Disease
of	O
Renografin	B-Chemical
76	I-Chemical
%	I-Chemical
was	O
compared	O
with	O
that	O
of	O
Hypaque	B-Chemical
76	I-Chemical
%	I-Chemical
by	O
selective	O
injection	O
of	O
each	O
into	O
the	O
right	O
coronary	O
artery	O
of	O
dogs	O
.	O

Vancomycin	B-Chemical
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	O
with	O
proven	O
infection	B-Disease
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-Chemical
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B-Disease
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
and	I-Disease
fibrillation	I-Disease
,	O
reduced	O
arrhythmia	B-Disease
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	B-Disease
rats	O
and	O
guinea	O
pigs	O
.	O

Flumazenil	B-Chemical
-	O
treated	O
patients	O
also	O
performed	O
significantly	O
better	O
on	O
the	O
Finger	O
-	O
to	O
-	O
Nose	O
Test	O
and	O
the	O
recall	O
of	O
pictures	O
shown	O
at	O
the	O
5	O
-	O
minute	O
assessment	O
.	O

We	O
studied	O
two	O
groups	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
with	O
(	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
+	O
LID	B-Disease
,	O
n	O
=	O
23	O
)	O
and	O
without	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
(	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
-	O
LID	B-Disease
,	O
n	O
=	O
10	O
)	O
,	O
and	O
age	O
-	O
matched	O
healthy	O
controls	O
.	O

We	O
recommend	O
that	O
hyperbaric	O
lignocaine	B-Chemical
should	O
be	O
administered	O
in	O
concentrations	O
not	O
greater	O
than	O
2	O
%	O
and	O
at	O
a	O
total	O
dose	O
preferably	O
not	O
exceeding	O
60	O
mg	O
.	O

Also	O
,	O
captopril	B-Chemical
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	B-Disease
invoked	O
by	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
in	O
SHR	O
.	O

Patients	O
receiving	O
amiodarone	B-Chemical
should	O
be	O
regularly	O
screened	O
with	O
respect	O
to	O
hepatic	O
enzyme	O
levels	O
.	O

NIMO	B-Chemical
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long	O
-	O
term	O
memory	O
caused	O
by	O
NTG	B-Chemical
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	B-Disease
.	O

Patients	O
with	O
aneurysmal	B-Disease
subarachnoid	I-Disease
hemorrhage	I-Disease
(	O
SAH	B-Disease
)	O
were	O
randomized	O
to	O
receive	O
either	O
ketoprofen	B-Chemical
,	O
100	O
mg	O
,	O
three	O
times	O
a	O
day	O
(	O
ketoprofen	B-Chemical
group	O
,	O
n	O
=	O
9	O
)	O
or	O
a	O
weak	O
NSAID	O
,	O
acetaminophen	B-Chemical
,	O
1	O
g	O
,	O
three	O
times	O
a	O
day	O
(	O
acetaminophen	B-Chemical
group	O
,	O
n	O
=	O
9	O
)	O
starting	O
immediately	O
after	O
the	O
diagnosis	O
of	O
aneurysmal	B-Disease
SAH	B-Disease
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure	B-Disease
-	O
induced	O
damage	O
.	O

CONCLUSION	O
:	O
The	O
use	O
of	O
light	O
propofol	B-Chemical
sedation	O
decreased	O
the	O
prevalence	O
of	O
postoperative	B-Disease
delirium	I-Disease
by	O
50	O
%	O
compared	O
with	O
deep	O
sedation	O
.	O

A	O
shift	O
to	O
the	O
left	O
in	O
the	O
dose	O
-	O
response	O
relation	O
and	O
fall	O
in	O
threshold	O
suggested	O
increased	O
sensitivity	O
to	O
norepinephrine	B-Chemical
after	O
treatment	O
.	O

Captopril	B-Chemical
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	B-Chemical
and	O
potassium	B-Chemical
,	O
endogenous	O
creatinine	B-Chemical
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

In	O
patients	O
premedicated	O
with	O
scopolamine	B-Chemical
+	O
morphine	B-Chemical
(	O
+	O
5	O
mg	O
nitrazepam	B-Chemical
the	O
evening	O
before	O
surgery	O
)	O
,	O
the	O
sleep	O
-	O
inducing	O
effect	O
of	O
midazolam	B-Chemical
0	O
.	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
was	O
clearly	O
slower	O
in	O
onset	O
than	O
that	O
of	O
thiopentone	B-Chemical
4	O
.	O
67	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
Somewhat	O
fewer	O
cardiovascular	O
and	O
local	O
sequelae	O
were	O
found	O
in	O
the	O
midazolam	B-Chemical
group	O
,	O
but	O
,	O
although	O
apnoea	B-Disease
occurred	O
less	O
often	O
in	O
the	O
midazolam	B-Chemical
group	O
it	O
lasted	O
longer	O
.	O

Further	O
long	O
-	O
term	O
follow	O
-	O
up	O
studies	O
will	O
be	O
necessary	O
to	O
fully	O
evaluate	O
the	O
impact	O
of	O
dexamethasone	B-Chemical
on	O
neurological	O
and	O
cognitive	O
development	O
.	O

The	O
symptoms	O
of	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
-	O
induced	O
psychosis	B-Disease
are	O
similar	O
to	O
those	O
of	O
paranoid	B-Disease
type	I-Disease
schizophrenia	I-Disease
.	O

Increased	O
serum	O
creatinine	B-Chemical
was	O
observed	O
in	O
73	O
%	O
of	O
patients	O
in	O
OD	O
versus	O
57	O
%	O
of	O
patients	O
in	O
TD	O
,	O
without	O
evidence	O
of	O
nephrotoxicity	B-Disease
.	O

Adjusted	O
relative	O
risks	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
were	O
1	O
.	O
0	O
,	O
0	O
.	O
81	O
,	O
0	O
.	O
99	O
,	O
1	O
.	O
26	O
,	O
and	O
1	O
.	O
91	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
01	O
)	O
and	O
of	O
stroke	B-Disease
were	O
1	O
.	O
0	O
,	O
0	O
.	O
52	O
,	O
1	O
.	O
23	O
,	O
2	O
.	O
22	O
,	O
and	O
2	O
.	O
57	O
(	O
P	O
for	O
trend	O
<	O
0	O
.	O
01	O
)	O
.	O

Urine	O
nitrite	B-Chemical
levels	O
were	O
significantly	O
increased	O
in	O
the	O
ADR	B-Chemical
-	O
nephropathy	B-Disease
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Myopathy	B-Disease
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	B-Chemical
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	B-Chemical
(	O
80	O
mg	O
)	O
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	O
of	O
fenfluramine	B-Chemical
and	O
dexfenfluramine	B-Chemical
had	O
valvular	B-Disease
disease	I-Disease
,	O
these	O
drugs	O
were	O
withdrawn	O
from	O
the	O
market	O
.	O

Cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
;	O
50	O
mg	O
/	O
kg	O
)	O
and	O
Fujimycine	B-Chemical
(	O
FK506	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
)	O
,	O
but	O
not	O
the	O
related	O
macrolide	B-Chemical
immunosuppressant	O
rapamycin	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
caused	O
a	O
reduction	O
of	O
glomerular	O
filtration	O
rate	O
,	O
degenerative	O
changes	O
of	O
proximal	O
tubular	O
epithelium	O
,	O
and	O
hypertrophy	B-Disease
of	O
the	O
juxtaglomerular	O
apparatus	O
in	O
male	O
Wistar	O
rats	O
when	O
given	O
for	O
10	O
days	O
.	O

Loss	O
of	O
glutamate	B-Chemical
decarboxylase	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
rat	O
dentate	O
gyrus	O
following	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	B-Disease
showed	O
changes	O
compatible	O
with	O
myelodysplastic	B-Disease
syndrome	I-Disease
(	O
MDS	B-Disease
)	O
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol	O
/	O
L	O
,	O
BAU	B-Chemical
possesses	O
minimal	O
anti	O
-	O
HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	B-Chemical
to	O
reverse	O
the	O
HIV	O
-	O
induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O

Because	O
the	O
protocol	O
was	O
long	O
and	O
involved	O
interventions	O
which	O
might	O
affect	O
the	O
determinations	O
,	O
we	O
also	O
studied	O
in	O
nine	O
patients	O
using	O
an	O
identical	O
protocol	O
except	O
that	O
ouabain	B-Chemical
administration	O
was	O
omitted	O
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B-Chemical
daunorubicin	B-Chemical
and	O
doxorubicin	B-Chemical
and	O
the	O
epipodophyllotoxin	B-Chemical
etoposide	B-Chemical
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B-Disease
and	O
cardiac	B-Disease
toxicity	I-Disease
limit	O
their	O
use	O
.	O

Haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	B-Chemical
NMDA	B-Chemical
receptor	O
antagonists	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
15	O
or	O
30	O
mmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
and	O
AP7	B-Chemical
(	O
10	O
or	O
20	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	B-Chemical
receptor	O
agonist	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
,	O
20	O
or	O
30	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
.	O

Diabetes	B-Disease
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

Long	O
-	O
term	O
effects	O
of	O
vincristine	B-Chemical
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Additionally	O
,	O
20	O
to	O
25	O
%	O
of	O
paracetamol	B-Chemical
-	O
treated	O
rats	O
developed	O
hyperplasia	B-Disease
of	O
the	O
bladder	O
epithelium	O
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	B-Disease
calculi	I-Disease
.	O

Nociceptive	O
effects	O
induced	O
by	O
intrathecal	O
administration	O
of	O
prostaglandin	B-Chemical
D2	I-Chemical
,	I-Chemical
E2	I-Chemical
,	I-Chemical
or	I-Chemical
F2	I-Chemical
alpha	I-Chemical
to	O
conscious	O
mice	O
.	O

When	O
BN	B-Chemical
52021	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	B-Disease
of	I-Disease
MBP	I-Disease
and	I-Disease
HR	I-Disease
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

This	O
agent	O
inhibits	O
Urd	B-Chemical
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	B-Chemical
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	B-Chemical
-	O
related	O
toxicity	B-Disease
.	O

Epicardial	O
mapping	O
suggested	O
that	O
verapamil	B-Chemical
promoted	O
AF	B-Disease
by	O
increasing	O
the	O
number	O
of	O
simultaneous	O
wavefronts	O
reflected	O
by	O
separate	O
zones	O
of	O
reactivation	O
in	O
each	O
cycle	O
.	O

RESULTS	O
:	O
The	O
MTD	O
of	O
cis	B-Chemical
-	I-Chemical
RA	I-Chemical
was	O
160	O
mg	O
/	O
m2	O
/	O
d	O
.	O

CONCLUSIONS	O
:	O
The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	O
sensitization	O
to	O
sera	O
containing	O
ex	O
vivo	O
-	O
prepared	O
dilevalol	B-Chemical
antigens	O
,	O
suggesting	O
the	O
involvement	O
of	O
an	O
immunologic	O
mechanism	O
in	O
dilevalol	B-Chemical
-	O
induced	O
liver	B-Disease
injury	I-Disease
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	B-Disease
toxicity	I-Disease
.	O

Amiodarone	B-Chemical
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	B-Disease
.	O

Peak	O
grip	O
force	O
in	O
ON	O
-	O
state	O
was	O
140	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
+	O
LID	B-Disease
than	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
-	O
LID	B-Disease
,	O
while	O
static	O
grip	O
force	O
was	O
increased	O
by	O
138	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
between	O
groups	O
.	O

In	O
mice	O
rendered	O
anemic	B-Disease
and	O
leukopenic	B-Disease
by	O
the	O
administration	O
of	O
AZT	B-Chemical
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1	O
.	O
5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	B-Chemical
plus	O
daily	O
BAU	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	B-Chemical
-	O
induced	O
anemia	B-Disease
and	O
leukopenia	B-Disease
(	O
P	O
less	O
than	O
.	O
05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4	O
.	O
9	O
%	O
,	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	B-Disease
.	O

However	O
,	O
these	O
other	O
potential	O
causes	O
of	O
seizure	B-Disease
were	O
ruled	O
out	O
.	O

A	O
case	O
of	O
acute	O
inflammatory	B-Disease
myopathy	I-Disease
associated	O
with	O
the	O
use	O
of	O
pravastatin	B-Chemical
,	O
a	O
new	O
hydrophilic	O
3	O
-	O
hydroxy	O
-	O
3	O
methylglutaril	O
coenzyme	O
A	O
reductase	O
inhibitor	O
,	O
is	O
reported	O
.	O

The	O
serotonin	B-Chemical
6	O
(	O
5	B-Chemical
-	I-Chemical
HT6	I-Chemical
)	O
receptor	O
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	O
,	O
such	O
as	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
,	O
and	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
-	O
induced	O
hyperactivity	B-Disease
in	O
rats	O
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
HT6	I-Chemical
receptor	O
antagonist	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
captopril	B-Chemical
-	O
induced	O
hypotension	B-Disease
treated	O
with	O
naloxone	B-Chemical
.	O

We	O
studied	O
the	O
effects	O
of	O
1	O
week	O
of	O
oral	O
hydrocortisone	B-Chemical
(	O
200	O
mg	O
/	O
day	O
)	O
on	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
,	O
forearm	O
vascular	O
resistance	O
,	O
and	O
norepinephrine	B-Chemical
spillover	O
to	O
plasma	O
in	O
eight	O
healthy	O
male	O
volunteers	O
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
)	O
.	O

Anticholinergic	O
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-Chemical
or	O
placebo	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
heart	O
rate	O
variability	O
and	O
LVPW	O
index	O
could	O
be	O
sensitive	O
indicators	O
for	O
cardiotoxicity	B-Disease
.	O

The	O
recommended	O
dose	O
for	O
phase	O
III	O
studies	O
is	O
paclitaxel	B-Chemical
185	O
mg	O
/	O
m2	O
and	O
carboplatin	B-Chemical
AUC	O
6	O
.	O

In	O
spontaneously	O
hypertensive	B-Disease
,	O
stroke	B-Disease
-	O
prone	O
rats	O
,	O
microinjection	O
of	O
methyldopa	B-Chemical
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-Chemical
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	B-Disease
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-Chemical
neurotoxin	O
5	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dihydroxytryptamine	I-Chemical
(	O
5	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
DHT	I-Chemical
)	O
injected	O
intracerebroventricularly	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
IP	O
administration	O
of	O
bupropion	B-Chemical
HCl	I-Chemical
120	O
mg	O
/	O
kg	O
by	O
bolus	O
injection	O
induced	O
convulsions	B-Disease
in	O
6	O
out	O
of	O
10	O
mice	O
(	O
60	O
%	O
of	O
convulsing	O
mice	O
)	O
in	O
group	O
1	O
.	O

Exclusion	O
criteria	O
were	O
asphyxia	B-Disease
,	O
malformations	B-Disease
,	O
major	O
surgical	O
interventions	O
,	O
small	O
for	O
gestational	O
age	O
,	O
intraventricular	O
haemorrhage	B-Disease
grades	O
III	O
and	O
IV	O
,	O
periventricular	B-Disease
leukomalacia	I-Disease
,	O
and	O
severe	O
psychomotor	B-Disease
retardation	I-Disease
.	O

Reye	B-Disease
syndrome	I-Disease
may	O
be	O
disappearing	O
from	O
Australia	O
despite	O
a	O
total	O
lack	O
of	O
association	O
with	O
salicylates	B-Chemical
or	O
aspirin	B-Chemical
ingestion	O
,	O
since	O
there	O
were	O
no	O
cases	O
found	O
at	O
The	O
Children	O
'	O
s	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O

Those	O
patients	O
receiving	O
AmB	B-Chemical
and	O
spironolactone	B-Chemical
required	O
significantly	O
less	O
potassium	B-Chemical
supplementation	O
to	O
maintain	O
their	O
plasma	O
potassium	B-Chemical
within	O
the	O
normal	O
range	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
.	O

Development	O
of	O
the	O
obstructive	B-Disease
sleep	I-Disease
apnea	I-Disease
syndrome	I-Disease
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	B-Chemical
therapy	O
.	O

Patients	O
participating	O
in	O
a	O
randomised	O
trial	O
of	O
anastrozole	B-Chemical
,	O
tamoxifen	B-Chemical
alone	O
or	O
combined	O
(	O
ATAC	O
)	O
(	O
n	O
=	O
94	O
)	O
and	O
a	O
group	O
of	O
women	O
without	O
breast	B-Disease
cancer	I-Disease
(	O
n	O
=	O
35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	O
measures	O
.	O

The	O
frequencies	O
of	O
HIT	B-Disease
after	O
liver	O
transplantation	O
and	O
platelet	O
factor	O
4	O
/	O
heparin	B-Chemical
-	O
reactive	O
antibody	O
(	O
HIT	B-Disease
antibody	O
)	O
positivity	O
in	O
liver	O
transplantation	O
patients	O
,	O
however	O
,	O
are	O
unknown	O
.	O

Among	O
women	O
aged	O
over	O
65	O
who	O
were	O
relatively	O
healthy	O
(	O
i	O
.	O
e	O
.	O
generally	O
fit	O
,	O
without	O
overt	O
disease	O
)	O
and	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B-Disease
.	O

Laboratory	O
variables	O
of	O
renal	O
function	O
[	O
serum	O
creatinine	B-Chemical
,	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
electrolytes	O
]	O
were	O
evaluated	O
before	O
initiation	O
of	O
therapy	O
and	O
every	O
2	O
days	O
,	O
until	O
termination	O
of	O
the	O
study	O
(	O
a	O
period	O
of	O
at	O
least	O
6	O
days	O
)	O
.	O

Leg	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
back	I-Disease
pain	I-Disease
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
Hibiscus	B-Chemical
rosa	I-Chemical
sinensis	I-Chemical
had	O
a	O
protective	O
role	O
against	O
reserpine	B-Chemical
-	O
induced	O
orofacial	O
dyskinesia	B-Disease
and	O
oxidative	O
stress	O
.	O

This	O
kit	O
may	O
provide	O
a	O
useful	O
method	O
to	O
test	O
heparin	B-Chemical
products	O
for	O
contamination	O
with	O
oversulfated	O
GAG	O
derivatives	O
.	O

The	O
high	O
-	O
dose	O
D	B-Chemical
-	I-Chemical
MED	I-Chemical
animals	O
were	O
flaccid	O
,	O
akinetic	B-Disease
,	O
and	O
lacked	O
a	O
startle	B-Disease
response	O
during	O
the	O
entire	O
experimental	O
period	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Moreover	O
,	O
PREGS	B-Chemical
is	O
able	O
to	O
reverse	O
the	O
amnesic	B-Disease
-	O
like	O
effects	O
of	O
NMDAR	O
and	O
GABA	B-Chemical
(	O
A	O
)	O
R	O
ligands	O
.	O

A	O
24	O
-	O
h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	B-Chemical
(	O
100mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	B-Disease
effects	O
of	O
CCl4	B-Chemical
,	O
CHCl3	B-Chemical
,	O
acetaminophen	B-Chemical
and	O
galactosamine	B-Chemical
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	B-Disease
)	O
effect	O
of	O
adriamycin	B-Chemical
administration	O
.	O

Significant	O
QTC	B-Disease
prolongation	I-Disease
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	B-Disease
and	O
elevation	O
of	O
cardiac	O
output	O
.	O

This	O
study	O
did	O
not	O
demonstrate	O
a	O
species	O
difference	O
regarding	O
the	O
role	O
of	O
the	O
amines	B-Chemical
on	O
the	O
pineal	O
in	O
spite	O
of	O
the	O
immature	O
blood	O
-	O
brain	O
barrier	O
in	O
the	O
young	O
chick	O
and	O
the	O
intact	O
barrier	O
in	O
the	O
rat	O
.	O

The	O
photodistribution	O
of	O
the	O
telangiectasia	B-Disease
suggests	O
a	O
significant	O
drug	O
/	O
light	O
interaction	O
.	O

Atorvastatin	B-Chemical
prevented	O
and	O
reversed	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O

In	O
conclusion	O
,	O
where	O
succinylcholine	B-Chemical
is	O
used	O
,	O
lidocaine	B-Chemical
is	O
proven	O
to	O
be	O
the	O
useful	O
pretreatment	O
agent	O
for	O
the	O
reduction	O
of	O
postoperative	B-Disease
myalgia	I-Disease
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	B-Chemical
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	B-Chemical
/	O
sparteine	B-Chemical
type	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B-Disease
fibrillation	I-Disease
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-Disease
back	I-Disease
pain	I-Disease
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-Chemical
loading	O
.	O

Seizures	B-Disease
associated	O
with	O
levofloxacin	B-Chemical
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	B-Chemical
for	O
metastatic	O
parameningeal	O
embryonal	B-Disease
rhabdomyosarcoma	I-Disease
.	O

Rats	O
that	O
received	O
ketanserin	B-Chemical
and	O
alfentanil	B-Chemical
exhibited	O
less	O
rearing	O
and	O
exploratory	O
behavior	O
at	O
the	O
end	O
of	O
the	O
60	O
-	O
min	O
recording	O
period	O
than	O
did	O
animals	O
that	O
received	O
ketanserin	B-Chemical
alone	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	B-Disease
coma	I-Disease
secondary	O
to	O
amiodarone	B-Chemical
-	O
induced	O
hypothyroidism	B-Disease
in	O
a	O
patient	O
with	O
severe	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
.	O

However	O
,	O
when	O
the	O
dose	O
is	O
adjusted	O
based	O
on	O
clinical	O
response	O
or	O
the	O
development	O
of	O
adverse	O
effects	O
,	O
75	O
%	O
of	O
patients	O
with	O
VT	B-Disease
or	O
VF	B-Disease
can	O
be	O
successfully	O
managed	O
with	O
amiodarone	B-Chemical
.	O

Heparin	B-Chemical
is	O
a	O
commonly	O
implemented	O
anticoagulant	O
used	O
to	O
treat	O
critically	O
ill	O
patients	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
even	O
though	O
OCT	B-Chemical
does	O
not	O
completely	O
prevent	O
the	O
occurrence	O
of	O
hypercalcemia	B-Disease
in	O
experimental	O
dogs	O
with	O
renal	B-Disease
insufficiency	I-Disease
,	O
it	O
may	O
be	O
of	O
use	O
in	O
the	O
management	O
of	O
secondary	B-Disease
hyperparathyroidism	I-Disease
because	O
it	O
does	O
not	O
induce	O
low	B-Disease
bone	I-Disease
turnover	I-Disease
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	O
the	O
risk	O
of	O
adynamic	B-Disease
bone	I-Disease
disease	I-Disease
.	O

Methamphetamine	B-Chemical
causes	O
alterations	O
in	O
the	O
MAP	O
kinase	O
-	O
related	O
pathways	O
in	O
the	O
brains	O
of	O
mice	O
that	O
display	O
increased	O
aggressiveness	B-Disease
.	O

A	O
murine	O
model	O
of	O
adenomyosis	B-Disease
:	O
the	O
effects	O
of	O
hyperprolactinemia	B-Disease
induced	O
by	O
fluoxetine	B-Chemical
hydrochloride	I-Chemical
,	O
a	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
,	O
on	O
adenomyosis	B-Disease
induction	O
in	O
Wistar	O
albino	O
rats	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	B-Disease
cancer	I-Disease
among	O
women	O
receiving	O
tamoxifen	B-Chemical
who	O
also	O
used	O
hormone	O
-	O
replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	B-Chemical
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin	B-Chemical
-	O
induced	O
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

A	O
phase	O
II	O
study	O
of	O
thalidomide	B-Chemical
in	O
advanced	O
metastatic	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Hyperalgesia	B-Disease
and	O
myoclonus	B-Disease
in	O
terminal	O
cancer	B-Disease
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	B-Chemical
.	O

Rosaceiform	O
dermatitis	B-Disease
associated	O
with	O
topical	O
tacrolimus	B-Chemical
treatment	O
.	O

Infusion	O
of	O
the	O
central	O
nervous	O
system	O
alpha2	B-Chemical
-	I-Chemical
adrenergic	I-Chemical
receptor	I-Chemical
agonist	I-Chemical
clonidine	B-Chemical
also	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
MAP	O
in	O
both	O
groups	O
of	O
SHR	O
that	O
were	O
fed	O
the	O
high	O
(	O
compared	O
with	O
the	O
basal	O
)	O
sodium	B-Chemical
chloride	I-Chemical
diet	O
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	B-Disease
within	I-Disease
the	I-Disease
subcortical	I-Disease
white	I-Disease
matter	I-Disease
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21	O
/	O
27	O
patients	O
)	O
.	O

Alkaline	O
phosphatase	O
and	O
glucose	B-Chemical
were	O
markedly	O
and	O
transiently	O
elevated	O
in	O
proximal	O
tubular	O
damage	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
showed	O
a	O
sustained	O
elevation	O
in	O
papillary	O
damage	O
.	O

Among	O
several	O
chemoconvulsants	O
,	O
bicuculline	B-Chemical
,	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartic	I-Chemical
acid	I-Chemical
and	O
BAY	B-Chemical
k	I-Chemical
-	I-Chemical
8644	I-Chemical
(	O
the	O
opener	O
of	O
L	O
-	O
type	O
calcium	B-Chemical
channels	O
)	O
reversed	O
the	O
protective	O
activity	O
of	O
loreclezole	B-Chemical
alone	O
and	O
its	O
combination	O
with	O
valproate	B-Chemical
.	O

A	O
minority	O
of	O
patients	O
evolve	O
to	O
psychosis	B-Disease
.	O

When	O
serum	O
prolactin	O
levels	O
normalized	O
in	O
all	O
four	O
subjects	O
(	O
mean	O
11	O
.	O
2	O
+	O
/	O
-	O
10	O
.	O
9	O
ng	O
/	O
mL	O
)	O
,	O
the	O
cabergoline	B-Chemical
dose	O
was	O
reduced	O
to	O
1	O
mg	O
/	O
week	O
in	O
three	O
of	O
four	O
subjects	O
.	O

DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	B-Chemical
in	O
combination	O
with	O
bortezomib	B-Chemical
/	O
dexamethasone	B-Chemical
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	B-Disease
.	O

Of	O
13	O
documented	O
fractures	B-Disease
,	O
3	O
occurred	O
after	O
risperidone	B-Chemical
and	O
SSRIs	O
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	O
with	O
hyperprolactinemia	B-Disease
.	O

RESULTS	O
:	O
In	O
Nx	O
dogs	O
,	O
OCT	B-Chemical
significantly	O
decreased	O
serum	O
PTH	O
levels	O
soon	O
after	O
the	O
induction	O
of	O
renal	B-Disease
insufficiency	I-Disease
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	B-Chemical
dependence	O
patients	O
.	O

High	O
-	O
dose	O
methylprednisolone	B-Chemical
may	O
do	O
more	O
harm	O
for	O
spinal	B-Disease
cord	I-Disease
injury	I-Disease
.	O

Patients	O
with	O
cerebrovascular	B-Disease
accidents	I-Disease
were	O
excluded	O
.	O

During	O
a	O
ten	O
-	O
year	O
period	O
,	O
348	O
women	O
were	O
studied	O
for	O
a	O
total	O
of	O
5	O
,	O
877	O
patient	O
months	O
in	O
four	O
separate	O
studies	O
relating	O
oral	B-Chemical
contraceptives	I-Chemical
to	O
changes	O
in	O
hematologic	O
parameters	O
.	O

Severe	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
associated	O
with	O
prophylactic	O
use	O
of	O
cefotetan	B-Chemical
in	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Dopamine	B-Chemical
antagonist	O
fluphenazine	B-Chemical
,	O
D	O
-	O
1	O
antagonist	O
SCH	B-Chemical
23390	I-Chemical
or	O
D	O
-	O
2	O
antagonist	O
sulpiride	B-Chemical
induced	O
catalepsy	B-Disease
.	O

Stimulus	O
-	O
induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine	B-Chemical
-	O
treated	O
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	B-Chemical
and	O
epinephrine	B-Chemical
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

Absolute	O
and	O
attributable	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
on	O
combined	O
cyproterone	B-Chemical
acetate	I-Chemical
and	O
ethinylestradiol	B-Chemical
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
DA	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	B-Chemical
warrant	O
more	O
intense	O
investigation	O
.	O

BACKGROUND	O
:	O
Hemolytic	B-Disease
anemia	I-Disease
is	O
one	O
of	O
the	O
major	O
adverse	O
events	O
of	O
the	O
combination	O
therapy	O
of	O
interferon	B-Chemical
and	O
ribavirin	B-Chemical
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
the	O
absolute	O
risk	O
of	O
VTE	B-Disease
among	O
Danish	O
women	O
on	O
COCs	B-Chemical
is	O
similar	O
to	O
that	O
among	O
women	O
taking	O
CPA	B-Chemical
/	O
EE	B-Chemical
.	O

Univariate	O
and	O
adjusted	O
analyses	O
showed	O
that	O
the	O
risk	O
increased	O
with	O
the	O
length	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
or	O
the	O
cumulative	O
dose	O
of	O
tamoxifen	B-Chemical
received	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	O
dose	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B-Disease
,	O
intractable	O
seizures	B-Disease
,	O
and	O
hypotonia	B-Disease
,	O
followed	O
by	O
significant	O
psychomotor	B-Disease
retardation	I-Disease
.	O

Neither	O
verapamil	B-Chemical
nor	O
diltiazem	B-Chemical
affected	O
atrial	O
conduction	O
in	O
the	O
presence	O
of	O
autonomic	O
blockade	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	B-Chemical
(	O
0	O
.	O
015	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
without	O
clinical	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O

The	O
present	O
results	O
thus	O
suggest	O
that	O
intra	O
-	O
arterial	O
PGE2	B-Chemical
,	O
given	O
near	O
the	O
bladder	O
,	O
may	O
initiate	O
micturition	O
in	O
the	O
normal	O
rat	O
chiefly	O
by	O
directly	O
contracting	O
the	O
smooth	O
muscle	O
of	O
the	O
detrusor	O
.	O

The	O
occurrence	O
of	O
a	O
myocardial	B-Disease
infarction	I-Disease
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	B-Chemical
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O

In	O
this	O
study	O
we	O
investigated	O
tolerability	O
and	O
reliability	O
of	O
nimesulide	B-Chemical
and	O
paracetamol	B-Chemical
in	O
a	O
very	O
large	O
number	O
of	O
patients	O
with	O
an	O
exclusive	O
well	O
-	O
documented	O
history	O
of	O
NSAID	B-Chemical
-	O
induced	O
urticaria	B-Disease
/	O
angioedema	B-Disease
.	O

50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
thiopental	B-Chemical
produced	O
respiratory	B-Disease
arrest	I-Disease
with	O
further	O
increase	O
in	O
GABA	B-Chemical
and	O
decrease	O
in	O
glutamate	B-Chemical
again	O
in	O
cortex	O
and	O
brain	O
stem	O
without	O
affecting	O
any	O
of	O
the	O
amino	B-Chemical
acids	I-Chemical
studied	O
in	O
four	O
regions	O
of	O
rat	O
brain	O
.	O

In	O
contrast	O
,	O
the	O
protein	O
abundances	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
H	B-Chemical
(	O
+	O
)	O
exchanger	O
type	O
3	O
(	O
NHE3	O
)	O
,	O
Na	B-Chemical
(	O
+	O
)	O
-	O
K	B-Chemical
(	O
+	O
)	O
-	O
2Cl	B-Chemical
(	O
-	O
)	O
cotransporter	O
(	O
BSC	O
-	O
1	O
)	O
,	O
and	O
thiazide	B-Chemical
-	O
sensitive	O
Na	B-Chemical
(	O
+	O
)	O
-	O
Cl	B-Chemical
(	O
-	O
)	O
cotransporter	O
(	O
TSC	O
)	O
were	O
decreased	O
.	O

A	O
correlation	O
was	O
found	O
between	O
serum	O
acid	O
protease	O
activity	O
and	O
prothrombin	O
time	O
,	O
and	O
the	O
increase	O
in	O
cathepsin	O
D	O
activity	O
was	O
sustained	O
over	O
several	O
days	O
compared	O
with	O
aspartate	B-Chemical
aminotransferase	O
,	O
which	O
showed	O
a	O
sharp	O
early	O
peak	O
and	O
then	O
a	O
fall	O
.	O

Fifty	O
-	O
six	O
days	O
after	O
initiation	O
of	O
the	O
treatment	O
the	O
patient	O
presented	O
hallucinations	B-Disease
that	O
only	O
stopped	O
after	O
the	O
withdrawal	O
of	O
psycho	O
-	O
active	O
drugs	O
and	O
tramadol	B-Chemical
.	O

Lithium	B-Chemical
carbonate	I-Chemical
may	O
be	O
a	O
factor	O
in	O
the	O
increasing	O
incidence	O
of	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
when	O
taken	O
during	O
early	O
pregnancy	O
.	O

If	O
agitation	B-Disease
becomes	O
marked	O
,	O
high	O
-	O
potency	O
neuroleptics	O
(	O
i	O
.	O
e	O
.	O
,	O
haloperidol	B-Chemical
)	O
may	O
be	O
effective	O
.	O

Aspirin	B-Chemical
or	O
salicylate	B-Chemical
ingestion	O
had	O
occurred	O
in	O
only	O
one	O
of	O
the	O
20	O
cases	O
(	O
5	O
%	O
)	O
,	O
and	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
had	O
been	O
administered	O
in	O
only	O
six	O
of	O
the	O
cases	O
(	O
30	O
%	O
)	O
.	O

In	O
addition	O
,	O
AMN082	B-Chemical
reduces	O
the	O
duration	O
of	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
in	O
a	O
mGlu7	O
receptor	O
-	O
dependent	O
manner	O
in	O
wild	O
-	O
type	O
but	O
not	O
mGlu7	O
receptor	O
knockout	O
mice	O
.	O

To	O
investigate	O
the	O
relationship	O
of	O
prostaglandins	B-Chemical
(	O
PGs	B-Chemical
)	O
to	O
seizure	B-Disease
induction	O
,	O
the	O
effects	O
of	O
six	O
PG	O
synthetase	O
inhibitors	O
on	O
convulsions	B-Disease
induced	O
by	O
flurothyl	B-Chemical
,	O
picrotoxin	B-Chemical
,	O
pentetrazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
,	O
electroshock	O
or	O
bicuculline	B-Chemical
were	O
evaluated	O
.	O

BACKGROUND	O
:	O
The	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	B-Chemical
-	O
induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
remains	O
unknown	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case	O
-	O
control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen	B-Chemical
-	O
exposed	O
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Visual	O
field	O
testing	O
confirmed	O
bilateral	O
central	O
-	O
caecal	O
scotomata	B-Disease
.	O

Status	B-Disease
epilepticus	I-Disease
in	O
rat	O
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
.	O

The	O
activities	O
of	O
the	O
lysosomal	O
enzymes	O
acid	O
and	O
neutral	O
protease	O
,	O
N	O
-	O
acetylglucosaminidase	O
,	O
and	O
acid	O
phosphatase	O
were	O
measured	O
in	O
the	O
serum	O
of	O
patients	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O

Coronary	B-Disease
artery	I-Disease
spasm	I-Disease
was	O
induced	O
by	O
a	O
provocative	O
test	O
.	O

Several	O
structurally	O
related	O
metabolites	O
of	O
progesterone	B-Chemical
(	O
3	B-Chemical
alpha	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
pregnane	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
ones	I-Chemical
)	O
and	O
deoxycorticosterone	B-Chemical
(	O
3	B-Chemical
alpha	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
pregnane	I-Chemical
-	I-Chemical
21	I-Chemical
-	I-Chemical
diol	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
ones	I-Chemical
)	O
and	O
their	O
3	O
beta	O
-	O
epimers	O
were	O
evaluated	O
for	O
protective	O
activity	O
against	O
pilocarpine	B-Chemical
-	O
,	O
kainic	B-Chemical
acid	I-Chemical
-	O
and	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
-	O
induced	O
seizures	B-Disease
in	O
mice	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	B-Chemical
II	I-Chemical
antagonist	O
,	O
valsartan	B-Chemical
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	B-Chemical
.	O

We	O
conclude	O
that	O
neuroactive	O
steroids	B-Chemical
are	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	B-Chemical
-	O
and	O
kainic	B-Chemical
acid	I-Chemical
-	O
induced	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
in	O
mice	O
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
status	B-Disease
epilepticus	I-Disease
in	O
humans	O
.	O

Chronic	O
CBZ	B-Chemical
also	O
decreased	O
the	O
incidence	O
of	O
seizure	B-Disease
-	O
related	O
mortality	O
in	O
the	O
cocaine	B-Chemical
-	O
injected	O
rats	O
.	O

The	O
extent	O
of	O
neuronal	B-Disease
injury	I-Disease
was	O
determined	O
by	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
triphenyltetrazolium	I-Chemical
staining	O
.	O

The	O
percentage	O
of	O
HIT	B-Disease
antibody	O
-	O
positive	O
patients	O
was	O
0	O
.	O
5	O
%	O
preoperatively	O
,	O
5	O
.	O
6	O
%	O
on	O
POD	O
7	O
,	O
and	O
5	O
.	O
6	O
%	O
on	O
POD	O
14	O
.	O

The	O
effects	O
of	O
N	B-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
-	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
a	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
synthase	O
inhibitor	O
and	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
,	O
a	O
NO	B-Chemical
precursor	O
,	O
were	O
investigated	O
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	B-Chemical
and	O
amisulpride	B-Chemical
.	O

Pathogenetic	O
mechanisms	O
of	O
cardiac	B-Disease
complications	I-Disease
in	O
cancer	B-Disease
patients	O
undergoing	O
chemotherapy	O
include	O
coronary	B-Disease
vasospasm	I-Disease
,	O
endothelial	O
damage	O
and	O
consequent	O
thrombus	B-Disease
formation	O
.	O

Valsartan	B-Chemical
,	O
a	O
new	O
angiotensin	B-Chemical
II	I-Chemical
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	B-Disease
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	B-Chemical
.	O

Transketolase	O
abnormality	O
in	O
tolazamide	B-Chemical
-	O
induced	O
Wernicke	B-Disease
'	I-Disease
s	I-Disease
encephalopathy	I-Disease
.	O

Cumulative	O
doses	O
of	O
doxorubicin	B-Chemical
were	O
225	O
-	O
550	O
mg	O
/	O
m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

Both	O
presented	O
in	O
the	O
emergency	O
room	O
with	O
profound	O
coma	B-Disease
,	O
hypotension	B-Disease
,	O
severe	O
hyperglycemia	B-Disease
,	O
and	O
acidosis	B-Disease
.	O

Experimental	O
cyclosporine	B-Chemical
nephrotoxicity	B-Disease
:	O
risk	O
of	O
concomitant	O
chemotherapy	O
.	O

CONCLUSIONS	O
:	O
Reduction	O
of	O
ribavirin	B-Chemical
at	O
hemoglobin	O
level	O
>	O
or	O
=	O
10	O
g	O
/	O
dl	O
is	O
suitable	O
in	O
terms	O
of	O
efficacy	O
and	O
side	O
effects	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium	B-Chemical
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

CONCLUSIONS	O
:	O
CBDCA	B-Chemical
is	O
neurotoxic	B-Disease
in	O
our	O
model	O
,	O
and	O
the	O
type	O
of	O
pathological	O
changes	O
it	O
induces	O
are	O
so	O
closely	O
similar	O
to	O
those	O
caused	O
by	O
CDDP	B-Chemical
that	O
it	O
is	O
probable	O
that	O
neurotoxicity	B-Disease
is	O
induced	O
in	O
the	O
two	O
drugs	O
by	O
the	O
same	O
mechanism	O
.	O

Prostaglandin	B-Chemical
F2	I-Chemical
alpha	I-Chemical
had	O
little	O
effect	O
on	O
pain	B-Disease
responses	O
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	B-Chemical
of	O
terbutaline	B-Chemical
-	O
induced	O
hypokalemia	B-Disease
.	O

The	O
protective	O
role	O
of	O
mangiferin	B-Chemical
was	O
analyzed	O
by	O
triphenyl	B-Chemical
tetrazolium	I-Chemical
chloride	I-Chemical
(	O
TTC	B-Chemical
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B-Disease
myocardium	I-Disease
.	O

Although	O
a	O
great	O
urinary	O
excretion	O
and	O
half	O
-	O
normal	O
plasma	O
levels	O
of	O
Ao	O
were	O
observed	O
on	O
day	O
6	O
after	O
PAN	B-Chemical
injection	O
,	O
when	O
NS	B-Disease
was	O
clearly	O
established	O
,	O
hepatic	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
.	O

Lifetime	O
treatment	O
of	O
mice	O
with	O
azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
produces	O
myelodysplasia	B-Disease
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

At	O
550	O
mg	O
/	O
m2	O
/	O
d	O
,	O
three	O
patients	O
experienced	O
nonurologic	O
toxicity	B-Disease
;	O
confusion	B-Disease
(	O
1	O
)	O
,	O
nausea	B-Disease
(	O
1	O
)	O
,	O
and	O
Grade	O
2	O
leukopenia	B-Disease
(	O
1	O
)	O
.	O

These	O
findings	O
demonstrate	O
that	O
overexpression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
doxorubicin	B-Chemical
-	O
induced	O
apoptosis	O
and	O
reduces	O
the	O
extent	O
of	O
acute	O
heart	B-Disease
failure	I-Disease
in	O
adult	O
mice	O
in	O
vivo	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	B-Disease
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O

Temporary	O
hearing	B-Disease
loss	I-Disease
is	O
a	O
known	O
toxicity	B-Disease
of	O
treatment	O
with	O
DFMO	B-Chemical
,	O
thus	O
a	O
comprehensive	O
approach	O
was	O
developed	O
to	O
analyze	O
serial	O
air	O
conduction	O
audiograms	O
.	O

Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	B-Chemical
(	O
acetylsalicylic	B-Chemical
acid	I-Chemical
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	B-Disease
associated	O
with	O
chronic	O
Urd	B-Chemical
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	B-Chemical
(	O
BAU	B-Chemical
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	B-Chemical
-	O
induced	O
anemia	B-Disease
and	O
leukopenia	B-Disease
was	O
assessed	O
.	O

